中信证券股份有限公司关于成都苑东生物制药股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为成都苑东 生物制药股份有限公司（以下简称"苑东生物"或"公司"）首次公开发行并在科 创板上市的持续督导保荐人，根据《证券发行上市保荐业务管理办法》《上海证券 交易所上市公司自律监管指引第 11 号——持续督导》《上市公司监管指引第 2 号 ——上市公司募集资金管理和使用的监管要求》《上海证券交易所上市公司募集资 金管理办法》《上海证券交易所科创板股票上市规则》等有关规定，对苑东生物 2024 年度募集资金的存放和使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一） 实际募集资金金额、资金到账时间 公司经中国证券监督管理委员会"证监许可[2020]1584 号"《关于同意成都苑东 生物制药股份有限公司首次公开发行股票注册的批复》同意注册，向社会公开发行 了人民币普通股（A 股）股票 3,009.00 万股，发行价为每股人民币为 44.36 元，共 计募集资金总额为人民币 1,334,792,400.00 元，扣除发行费用（不含税）人 ...

关于成都苑东生物制药股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为成都 苑东生物制药股份有限公司（以下简称"苑东生物"或"公司"）首次公开发行 股票并上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股 票上市规则》等相关法律、法规和规范性文件的规定，对苑东生物使用部分闲置 募集资金进行现金管理事项进行了核查，核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意成都苑东生物制药股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕1584 号），公司向社会 公开发行人民币普通股 30,090,000 股，每股面值人民币 1.00 元，每股发行价为 人民币 44.36 元，合计募集资金人民币 1,334,792,400.00 元，扣除发行费用人民 币 112,091,740.59 元（不含税）后，募集资金净额为人民币 ...

成都苑东生物制药股份有限公司 2024年度独立董事述职报告（程增江） 本人于2024年12月27日当选为成都苑东生物制药股份有限公司（以下简称"公司"） 第四届董事会的独立董事，本人独立董事的履职期间为2024年12月27日-2024年12月31 日。现将本人的相关情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 公司于2024年12月27日完成了第四届董事会成员的选举和专委会成员的选举，本人 被选举为公司第四届董事会的独立董事，并任董事会提名委员会主任委员（召集人）、 审计委员会委员和战略委员会委员。本人工作履历等情况如下： （二）独立性情况说明 作为公司的独立董事，本人具备中国证监会《上市公司独立董事管理办法》中所 要求的独立性，本人及直系亲属、主要社会关系均未在公司及其附属企业担任除独立 董事之外的其他职务；没有为公司及其附属企业提供财务、法律、管理咨询、技术咨 询等服务；除独立董事津贴外，没有从公司及其主要股东或有利害关系的机构和人员 处取得额外的、未予披露的其他利益，能够进行客观、独立的专业判断，不存在影响 独立性的情况。 二、独立董事年度履职概况 本人履职期间为20 ...

成都苑东生物制药股份有限公司 2024年度独立董事述职报告（方芳） 作为成都苑东生物制药股份有限公司（以下简称"公司"）独立董事，本人在任职期 内严格依照《公司法》、《上海证券交易所科创板股票上市规则》、《上市公司治理准则》、 《上市公司独立董事管理办法》等法律规定、规范性文件以及《公司章程》、《公司独立董 事工作制度》等有关规定和要求，忠实、勤勉、尽责的履行独立董事职责，切实维护公司 以及全体股东尤其是中小股东的合法权益。现将本人在2024年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 公司于2021年12月23日召开2021年第二次临时股东大会选举产生了第三届董事会 成员，本人当选为公司第三届独立董事，并任董事会审计委员会主任委员和董事会薪 酬与考核委员会委员。 公司于2024年12月27日完成了第四届董事会成员的选举和专委会成员的选举，本 人继续被选举为公司第四届董事会的独立董事，并任董事会审计委员会主任委员和董 事会薪酬与考核委员会委员。本人工作履历等情况如下： 方芳，女，1982年3月出生，中国国籍，无境外永久居留权，会计学博士。2012 年7月至今就职于北 ...

成都苑东生物制药股份有限公司 2024年度独立董事述职报告（JIN LI） 作为成都苑东生物制药股份有限公司（以下简称"公司"）独立董事，本人在任职期 内严格依照《公司法》、《上海证券交易所科创板股票上市规则》、《上市公司治理准则》、 《上市公司独立董事管理办法》等法律规定、规范性文件以及《公司章程》、《公司独立 董事工作制度》等有关规定和要求，忠实、勤勉、尽责的履行独立董事职责，切实维护公 司以及全体股东尤其是中小股东的合法权益。现将本人任职期间（2024年1月1日-2024年12月 27日）的履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 公司于2021年12月23日召开2021年第二次临时股东大会选举产生了第三届董事会 成员，本人当选为公司第三届独立董事，并任董事会提名委员会主任委员（召集人）、 审计委员会委员和战略委员会委员。本人工作履历等情况如下： JIN LI，男，1965年5月生，美国国籍，博士。2018年起担任公司独立董事，现 任北京欧博方医药科技有限公司董事长、总经理，北京元博方医药科技有限公司经 理等职务。曾就职于美国辉瑞制药公司等公司。 （二）本人任 ...

成都苑东生物制药股份有限公司 2024年度独立董事述职报告（彭龙） 作为成都苑东生物制药股份有限公司（以下简称"公司"）独立董事，本人在任职期 内严格依照《公司法》、《上海证券交易所科创板股票上市规则》、《上市公司治理准则》、 《上市公司独立董事管理办法》等法律法规及《公司章程》、《公司独立董事工作制度》等 有关规定和要求，忠实、勤勉、尽责的履行独立董事职责，切实维护公司以及全体股东尤 其是中小股东的合法权益。现将本人在2024年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 因公司原独立董事尚姝女士任期已满6年，公司已于2023年4月12日和2023年5月5 日分别召开第三届董事会第八次会议及2022年年度股东大会审议通过了《关于独立董 事任期届满暨选举独立董事的议案》，本人当选为公司第三届独立董事，并任董事会 薪酬与考核委员会主任委员（召集人）、董事会审计委员会委员、董事会提名委员会 委员。 公司于2024年12月27日完成了第四届董事会成员的选举和专委会成员的选举，本 人继续被选举为公司第四届董事会的独立董事，并任董事会薪酬与考核委员会主任委 员（召集人）、董事会 ...

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 王颖 | 6159.30 | 34.89 | 不变 | | 闵洲 | 1396.50 | 7.91 | 不变 | | 成都楠苑投资合伙企业(有限合伙) | 761.46 | 4.31 | 不变 | | 袁明旭 | 294.00 | 1.67 | 不变 | | 王荣华 | 294.00 | 1.67 | 不变 | | 国泰佳泰股票专项型养老金产品-招商银行股份有限 公司 | 232.23 | 1.32 | -40.08 | | 张大明 | 220.50 | 1.25 | 不变 | | 陈增贵 | 220.50 | 1.25 | 不变 | | 成都竹苑投资合伙企业(有限合伙) | 183.02 | 1.04 | 不变 | | 成都苑东生物制药股份有限公司-2024年员工持股计 划 | 160.38 | 0.91 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 国泰聚信价值优势灵活配置混合A | 324.46 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 305,640,342.42, a decrease of 2.97% compared to CNY 314,990,089.28 in the same period last year[4] - Net profit attributable to shareholders was CNY 60,590,351.64, down 19.22% from CNY 75,010,084.96 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 46,468,704.84, a decrease of 10.79% compared to CNY 52,091,879.13 in the previous year[4] - The net profit for Q1 2025 was CNY 60,590,351.64, a decrease of 19.3% compared to CNY 75,010,084.96 in Q1 2024[20] - Operating profit for Q1 2025 was CNY 62,469,083.72, down from CNY 80,220,974.65 in the same period last year, reflecting a decline of 22.1%[20] - The company reported a net profit margin of approximately 15.1% for Q1 2025, based on the revenue and operating costs figures[19] - The total comprehensive income for Q1 2025 was CNY 60,590,351.64, a decrease of 19.3% from CNY 75,010,084.96 in Q1 2024[21] Cash Flow and Investments - The net cash flow from operating activities was CNY 48,957,799.77, down 31.90% from CNY 71,892,080.50 year-on-year[4] - The cash flow from operating activities for Q1 2025 was CNY 48,957,799.77, a decrease of 32.0% compared to CNY 71,892,080.50 in Q1 2024[24] - The company reported a net cash outflow from investing activities of CNY 551,307,978.14 in Q1 2025, compared to a net inflow of CNY 41,296,601.12 in Q1 2024[24] - Cash and cash equivalents as of March 31, 2025, were RMB 496,753,707.66, down from RMB 971,404,996.50 as of December 31, 2024[14] - Cash and cash equivalents at the end of Q1 2025 were CNY 490,995,537.76, down from CNY 816,632,829.91 at the end of Q1 2024[25] Research and Development - Research and development expenses totaled CNY 61,855,238.88, representing 20.24% of operating revenue, an increase of 0.19 percentage points compared to 20.05% last year[5] - Research and development expenses rose to CNY 61,097,854.94 in Q1 2025, up 12.5% from CNY 54,184,914.96 in Q1 2024[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,460,845,346.04, an increase of 1.79% from CNY 3,400,127,500.60 at the end of the previous year[5] - Total assets increased to RMB 3,460,845,346.04 as of March 31, 2025, compared to RMB 3,400,127,500.60 at the end of 2024[16] - Total liabilities decreased slightly to RMB 697,883,870.78 from RMB 702,205,924.57 at the end of 2024[17] - Shareholders' equity increased to RMB 2,762,961,475.26 as of March 31, 2025, compared to RMB 2,697,921,576.03 at the end of 2024[17] - Inventory as of March 31, 2025, was RMB 213,618,891.26, up from RMB 190,086,164.97 at the end of 2024[15] - Short-term borrowings increased to RMB 103,385,606.87 from RMB 74,437,854.77 at the end of 2024[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,091[10] - The largest shareholder, Wang Ying, holds 34.89% of the shares, totaling 61,593,000 shares[11] Earnings Per Share - The basic and diluted earnings per share for Q1 2025 were both CNY 0.34, down from CNY 0.43 in Q1 2024[21] Financial Expenses - The company incurred financial expenses of CNY -1,829,246.74 in Q1 2025, compared to CNY -944,567.73 in Q1 2024, indicating an increase in financial costs[20]

Financial Performance - The company achieved operating revenue of CNY 1,349,755,302.66 in 2024, representing a year-on-year increase of 20.82%[23] - Net profit attributable to shareholders reached CNY 238,234,159.30, up 5.15% compared to the previous year[23] - The net profit after deducting non-recurring gains and losses was CNY 174,764,929.24, reflecting a growth of 10.90% year-on-year[23] - The net cash flow from operating activities was CNY 263,240,369.25, a decrease of 4.36% from the previous year[24] - The company's total assets increased to CNY 3,400,127,500.60, marking a 1.59% rise compared to the end of 2023[24] - Basic earnings per share rose to CNY 1.36, an increase of 6.25% from the previous year[25] - The company reported a significant growth in the CMO/CDMO business, with revenue soaring by 111.59% to CNY 65.20 million[38] - The company achieved total operating revenue of CNY 1,349,755,302.66, representing a year-on-year growth of 20.82%[126] - The net profit attributable to shareholders was CNY 238,234,200, reflecting a year-on-year increase of 5.15%[126] Research and Development - The R&D expenditure accounted for 21.31% of operating revenue, a decrease of 0.72 percentage points from the previous year[25] - Total R&D investment reached approximately CNY 287.62 million, an increase of 16.88% compared to the previous year, with a significant rise in capitalized R&D investment by 212.86%[89] - The company invests over 20% of its revenue in R&D, with nearly 30% allocated to innovative drugs, surpassing the industry average[72] - The company has established six drug research institutes across Chengdu, Meishan, and Shanghai, covering the entire pharmaceutical value chain[105] - The company is focusing on innovative synthesis techniques to enhance product quality and reduce environmental impact, particularly in the production of raw materials[102] - The company has made significant progress in its R&D pipeline, with one Class 1 new drug entering Phase III clinical trials and three Class 1 innovative drugs receiving clinical trial approvals[165] - The company has 19 products under review for market approval, with 11 products approved for clinical trials[171] - The company has a total of 31 raw materials under review for market approval, indicating a strong pipeline[172] Product Development and Market Expansion - The company plans to continue expanding its market presence and enhancing its product offerings in the coming years[26] - The company has launched new products, including Nalbuphine Hydrochloride Injection, with successful market access in multiple provinces[47] - The company is actively pursuing market expansion through innovative product development and strategic partnerships[10][12] - The company is focusing on expanding its product offerings in cardiovascular and respiratory treatments, with multiple new drugs in the pipeline[166] - The company has submitted multiple product applications, including EP-0124A+EP-0160I and EP-0125SP, with market potential in the U.S. and Europe[102] - The company has submitted registration applications for multiple new products, including a compound morphine sustained-release capsule and a new formulation of apatinib, with expected market entry soon[10][12][13] Compliance and Governance - The company has a standard unqualified audit report from the accounting firm Xin Yong Zhong He[6] - The company has no non-operating fund occupation by controlling shareholders or related parties[9] - The company has no violations of decision-making procedures regarding external guarantees[10] - The company has not disclosed any special arrangements for corporate governance[8] - The company has strengthened its quality management system, passing 13 GMP compliance checks and receiving multiple awards for quality management excellence[45] - The company is enhancing compliance management systems in response to stricter anti-corruption measures in the pharmaceutical industry[158] Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China achieved a revenue of CNY 25,298.5 billion in 2024, with a profit of CNY 3,420.7 billion, reflecting a year-on-year profit decline of 1.1%[64] - The profit margin for the pharmaceutical manufacturing industry is approximately 13.52%, which is 8.13 percentage points higher than the overall level of large-scale industrial enterprises[64] - The global pharmaceutical market is projected to reach $2.3 trillion by 2028, with a CAGR of 5-8%[192] - China's pharmaceutical market has grown from $103 billion in 2014 to $163 billion in 2023, expected to reach $197 billion by 2028, with a CAGR of 3.8%[196] - The market share of innovative drugs in China increased from 20% in 2014 to 29% in 2023, with a projected CAGR of 7.5% for the next five years[197] Strategic Initiatives - The company is actively pursuing mergers and acquisitions, supported by recent government policies aimed at promoting high-quality development in the capital market[80] - The company is focusing on high-end formulations to navigate the complex market environment, driven by ongoing centralized procurement and DRG/DIP payment reforms[158] - The company aims to improve overall cost management and refine operations to support high-quality and differentiated development[159] - The company is committed to a research and development philosophy centered on creating differentiated clinical advantages, aiming to strengthen market competitiveness[159] Risk Management - The company has detailed various risks in its operations and has outlined measures to mitigate these risks in the management discussion section[5] - The company faces risks from national centralized procurement policies, which may lead to price reductions and impact operational performance[116] - The company faces risks from intensified competition in the pharmaceutical industry, particularly from Indian manufacturers and domestic market saturation[122] - The company is adapting to regulatory changes in the pharmaceutical industry, which may impact operational strategies and profit margins[120]

成都苑东生物制药股份有限公司 董事会审计委员会对会计师事务所 履行监督职责情况报告 成都苑东生物制药股份有限公司（以下简称公司）聘请信永中和会计师事务 所（特殊普通合伙）（以下简称"信永中和"）作为公司 2024 年度年报审计师。 根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务 所管理办法》等规定和要求，公司董事会审计委员会本着勤勉尽责的原则，恪尽 职守，认真履职。现将董事会审计委员会对会计师事务所履行监督职责的情况汇 报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 信永中和最早可追溯到 1986 年成立的中信会计师事务所，于 2012 年由有限 责任公司转制为特殊普通合伙制事务所，注册地址为北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层，首席合伙人为谭小青先生。信永中和拥有财政部颁发的 会计师事务所执业证书，2010 年成为首批获准从事 H 股企业审计业务的会计师 事务所，新证券法实施前具有证券、期货业务许可证，2020 年在财政部完成从 事证券服务业务会计师事务所备案。 截至 2024 年 12 月 31 日，信永中和合伙人（股东）259 人， ...